FULGENT GENETICS, INC. Interest Income (Expense), Net
FULGENT GENETICS, INC. (FLGT) reported Interest Income (Expense), Net of $3.09 million for the 3-month period ending 2022-12-31, per its 10-K filed 2023-02-28.
Discontinued › Income Statement › Other Income
us-gaap:InterestIncomeExpenseNet · last filed 2023-02-28
- FULGENT GENETICS, INC. interest income (expense), net for the quarter ending 2022-12-31 was $3.09M.
- FULGENT GENETICS, INC. interest income (expense), net for the quarter ending 2022-09-30 was $1.41M, a 183.27% increase year-over-year.
- FULGENT GENETICS, INC. interest income (expense), net for the quarter ending 2022-06-30 was $958.00K, a 58.61% increase year-over-year.
- FULGENT GENETICS, INC. interest income (expense), net for the quarter ending 2022-03-31 was $45.00K, a 84.04% decline year-over-year.
| Period end | Interest Income (Expense), Net 3 month | Interest Income (Expense), Net 6 month | Interest Income (Expense), Net 9 month | Interest Income (Expense), Net 12 month |
|---|---|---|---|---|
| 2022-12-31 | $3.09M 10-K · filed 2023-02-28 | $4.50M derived: sum of 2 quarters · filed 2023-02-28 | $5.45M derived: sum of 3 quarters · filed 2023-02-28 | $5.50M derived: sum of 4 quarters · filed 2023-02-28 |
| 2022-09-30 | $1.41M 10-K · filed 2023-02-28 | $2.36M derived: sum of 2 quarters · filed 2023-02-28 | $2.41M derived: sum of 3 quarters · filed 2023-02-28 | $2.37M derived: sum of 4 quarters · filed 2023-02-28 |
| 2022-06-30 | $958.00K 10-K · filed 2023-02-28 | $1.00M derived: sum of 2 quarters · filed 2023-02-28 | $968.00K derived: sum of 3 quarters · filed 2023-02-28 | $1.46M derived: sum of 4 quarters · filed 2023-02-28 |
| 2022-03-31 | $45.00K 10-K · filed 2023-02-28 | $10.00K derived: sum of 2 quarters · filed 2023-02-28 | $506.00K derived: sum of 3 quarters · filed 2023-02-28 | $1.11M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-12-31 | -$35.00K 10-K · filed 2023-02-28 | $461.00K derived: sum of 2 quarters · filed 2023-02-28 | $1.06M derived: sum of 3 quarters · filed 2023-02-28 | $1.35M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-09-30 | $496.00K 10-K · filed 2023-02-28 | $1.10M derived: sum of 2 quarters · filed 2023-02-28 | $1.38M derived: sum of 3 quarters · filed 2023-02-28 | $1.97M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $604.00K 10-K · filed 2023-02-28 | $886.00K derived: sum of 2 quarters · filed 2023-02-28 | $1.48M derived: sum of 3 quarters · filed 2023-02-28 | $1.90M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $282.00K 10-K · filed 2023-02-28 | $871.00K derived: sum of 2 quarters · filed 2023-02-28 | $1.29M derived: sum of 3 quarters · filed 2023-02-28 | $1.57M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $589.00K 10-K · filed 2022-02-28 | $1.01M derived: sum of 2 quarters · filed 2022-02-28 | $1.28M derived: sum of 3 quarters · filed 2022-02-28 | $1.53M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-09-30 | $421.00K 10-K · filed 2022-02-28 | $696.00K derived: sum of 2 quarters · filed 2022-02-28 | $937.00K derived: sum of 3 quarters · filed 2022-02-28 | |
| 2020-06-30 | $275.00K 10-K · filed 2022-02-28 | $516.00K derived: sum of 2 quarters · filed 2022-02-28 | ||
| 2020-03-31 | $241.00K 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B |